Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2023

The 28th Congress of the European Hematology Association

08–11 June 2023 | Frankfurt, Germany / Online

The 28th Congress of the European Hematology Association (EHA) 2023 was held in Frankfurt, Germany, from June 8-11, 2023, and continued virtually on June 14-15, 2023. This meeting was an opportunity for world-leading experts to come together to share cutting-edge updates in the diagnosis and treatment of hematological malignancies.

View all videos

The José Carreras award and a history of immunotherapy in Ph+ ALL

Robin Foà • 11 Jun 2023

Top highlights from ASCO & EHA 2023

Mohamad Mohty • 10 Jun 2023

MASTER final analysis: quadruplet induction therapy, ASCT & MRD-adapted treatment cessation in NDMM

Luciano Costa • 10 Jun 2023

Identifying and managing patients at high risk of developing toxicities following CAR-T therapy

Kai Rejeski • 10 Jun 2023

MORPHO: gilteritinib as post-transplant maintenance therapy in patients with FLT3-ITD AML

Mark Levis • 9 Jun 2023

REVIVE: targeted therapy for uncontrolled erythrocytosis in PV with rusfertide

Ronald Hoffman • 9 Jun 2023

ADCLEC.syn1 CAR: ADGRE2-targeting 28z1XX-CAR and a CLEC12A-targeting CCR in humanized AML models

Sascha Haubner • 9 Jun 2023

6-year results of CLL14: venetoclax-obinutuzumab for previously untreated CLL

Othman Al-Sawaf • 9 Jun 2023

Multimodal prediction of survival in myeloma: combining MRD testing with MALDI-TOF MS & imaging

Rakesh Popat • 11 Jun 2023

MagnetisMM-3 extended follow up results: elranatamab monotherapy in R/R multiple myeloma

Mohamad Mohty • 10 Jun 2023

LBA: results of REVIVE – rusfertide in patients with polycythemia vera

Marina Kremyanskaya • 10 Jun 2023

The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs

Jean-Jacques Kiladjian • 13 Jun 2023

LBA: gilteritinib as post-transplant maintenance therapy in FLT3-ITD AML

Mark Levis • 9 Jun 2023

LBA: KOMET-001 – ziftomenib monotherapy in R/R NPM1-mutated AML

Eunice Wang • 9 Jun 2023

IMerge update: continuous transfusion independence & disease modification with imetelstat in LR-MDS

Amer Zeidan • 10 Jun 2023

COMMANDS study: efficacy & safety results and biomarker analysis

Uwe Platzbecker • 14 Jun 2023

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLL

Jennifer Brown • 9 Jun 2023

Latest advances in BTK inhibitors from EHA 2023

Lydia Scarfò et al. • 24 Jun 2023

Updates in CAR-T and bispecific antibodies for LBCL from EHA 2023

Gloria Iacoboni et al. • 24 Jun 2023

Phase II study of brentuximab vedotin + CHP in patients with PTCL with less than 10% CD30 expression

Swaminathan Iyer • 10 Jun 2023

Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy

Salomon Manier • 9 Jun 2023

Issues in CAR-T slot allocation in lymphoma and multiple myeloma

Nico Gagelmann • 11 Jun 2023

Final results of CARTITUDE-1: cilta-cel in heavily pretreated patients with R/R multiple myeloma

Nikhil Munshi • 9 Jun 2023

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

Wojciech Jurczak • 10 Jun 2023